UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 13, 2004
Biogen Idec Inc. | ||
(Exact name of registrant as specified in its charter) | ||
Delaware | 0-19311 | 33-0112644 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
||
14 Cambridge Center, Cambridge, Massachusetts | 02142 | |
(Address of principal executive offices) | (Zip Code) | |
Registrants telephone number, including area code: (617) 679-2000
Not Applicable | ||
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events
William H. Rastetter, Ph.D., the registrants Executive Chairman, entered into two Rule 10b5-1 sales plans on December 13, 2004. One plan covers shares held in trust and the second plan covers stock options. Sales under the plans are scheduled to take place between February 15, 2005 and December 30, 2005. The maximum number of shares which can be sold under the plans is 401,926.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Biogen Idec Inc. | ||||
By: | /s/ Anne Marie Cook
Anne Marie Cook Vice President, Chief Corporate Counsel |
Date: December 20, 2004